Marshall Wace, LLP Sellas Life Sciences Group, Inc. Call Options Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SLS
# of Institutions
74Shares Held
25.3MCall Options Held
538KPut Options Held
26.3K-
Vanguard Group Inc Valley Forge, PA6.65MShares$10.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$3.54 Million0.0% of portfolio
-
State Street Corp Boston, MA1.11MShares$1.79 Million0.0% of portfolio
-
Nuveen, LLC Charlotte, NC971KShares$1.56 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL698KShares$1.12 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $33.1M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...